• Diasorin Signs Exclusive U.S. Distribution Deal with Fisher Scientific for in-house testing platform
SALUGGIA, Italy – Diasorin announced on January 26, 2026, it has signed an exclusive distribution agreement with Fisher Scientific to supply its LIAISON NES molecular point-of-care platform to the U.S. hospital market.
The agreement follows recent U.S. Food and Drug Administration clearance for the platform’s first assay, a panel for Flu A/B, RSV, and COVID-19.
What is new?
The Italian diagnostics company Diasorin has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific, for its LIAISON NES molecular point-of-care (POC) platform within the U.S. hospital market.
The deal, announced after the platform and its first respiratory panel received 510(k) clearance and a CLIA-waiver from the U.S. FDA, grants Fisher Scientific sole distribution rights in this channel.
Key Details
The LIAISON NES is a next-generation molecular POC system designed to provide rapid, lab-quality diagnostic testing in decentralized, near-patient settings. Its fully automated workflow requires only a few seconds of hands-on time and can deliver results in approximately 15 minutes. This design aims to enable timely clinical decisions while reducing the need for specialized laboratory personnel.
The first assay available for the platform is a combined panel for Influenza A/B, Respiratory Syncytial Virus (RSV), and COVID-19.
Market Impact
This partnership targets one of the world’s largest markets for molecular respiratory testing, which includes over 7,000 hospitals in the United States. The agreement leverages Fisher Scientific’s established footprint across the U.S. hospital channel to accelerate the introduction and adoption of the LIAISON NES® platform. The deal is intended to strengthen Diasorin’s commercial capabilities and support its access to major U.S. Integrated Delivery Networks (IDNs), complementing the company’s existing sales organization.
Next Steps
Diasorin is also working to finalize additional distribution agreements to cover the non-acute market segment. This includes the approximately 130,000 Physician Office Labs (POLs) in the United States. The company stated this is part of a broader go-to-market strategy to ensure comprehensive coverage across all key customer categories.
About this company
Diasorin is a global in-vitro diagnostic (IVD) company headquartered in Italy and listed on the Italian Stock Exchange in the FTSE MIB Index. With over 50 years in the field, the company develops, produces, and markets reagent kits for diagnostic laboratories worldwide.
Since 2021, Diasorin has also been active in the life sciences business.
Diasorin Boosts Revenues, Profitability, Raises 2024 Revenue Forecast
Diasorin Submitted 510(K) For Liaison Plex Gram-Positive Blood Culture Assay